Law360 interviewed Peter Goss for an article discussing noteworthy product liability cases that are currently pending. Goss cited the federal multi-district litigation over the cholesterol drug Lipitor and the increased risk of diabetes allegedly associated with its use. “Millions of Americans have diabetes, and millions of people take Lipitor, and it would potentially open the door to some significant litigation if the plaintiffs were to prevail in an early bellwether trial in this litigation,” said Goss. Goss also noted that the plaintiffs in the Zoloft birth defects litigation have yet to win a trial, and commented that “[W]e won’t be seeing much more of this birth defect litigation with respect to SSRIs” if the plaintiffs are unable to prevail in upcoming federal bellwether trials. The article is available to Law360 subscribers here.
Mr. Goss focuses his national practice on pharmaceutical and medical device product liability litigation and toxic torts. He has represented global pharmaceutical, medical technology, and chemical firms in hundreds of cases. Mr. Goss often serves as “science counsel” in life sciences litigation. He collaborates with leading experts to present complex medical and scientific evidence, both in dispositive motions and at trial. He is a frequent commentator on scientific evidence, products liability, and legal developments of interest to FDA-regulated industries.
Blackwell Burke P.A., a litigation and trial boutique in Minneapolis, Minnesota, serves as national trial and litigation counsel for numerous Fortune 500 companies. The firm has extensive experience in class action defense, commercial litigation, food industry defense, labor and employment, and products liability. The firm has represented corporate clients in state and federal courts throughout the country and in several foreign jurisdictions.